nodes	percent_of_prediction	percent_of_DWPC	metapath
Vapreotide—SSTR2—GPCRs, Other—DRD4—conduct disorder	0.0533	0.0533	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0384	0.0384	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0368	0.0368	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0354	0.0354	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Other—HTR2A—conduct disorder	0.0348	0.0348	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CGA—conduct disorder	0.0292	0.0292	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.029	0.029	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0279	0.0279	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.0277	0.0277	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—DRD4—conduct disorder	0.027	0.027	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CGA—conduct disorder	0.027	0.027	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0251	0.0251	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—DRD4—conduct disorder	0.0249	0.0249	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0231	0.0231	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.0226	0.0226	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.0218	0.0218	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0215	0.0215	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CGA—conduct disorder	0.0212	0.0212	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0198	0.0198	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.0178	0.0178	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CGA—conduct disorder	0.0165	0.0165	CbGpPWpGaD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0164	0.0164	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—DRD4—conduct disorder	0.0164	0.0164	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0156	0.0156	CbGpPWpGaD
Vapreotide—TACR1—G alpha (q) signalling events—HTR2A—conduct disorder	0.0154	0.0154	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CGA—conduct disorder	0.0152	0.0152	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0151	0.0151	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—DRD4—conduct disorder	0.0151	0.0151	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CGA—conduct disorder	0.015	0.015	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.014	0.014	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CGA—conduct disorder	0.0138	0.0138	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.0138	0.0138	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0129	0.0129	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CGA—conduct disorder	0.012	0.012	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.012	0.012	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—DRD4—conduct disorder	0.0119	0.0119	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CGA—conduct disorder	0.0109	0.0109	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—HTR2A—conduct disorder	0.0107	0.0107	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0102	0.0102	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—HTR2A—conduct disorder	0.00985	0.00985	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00942	0.00942	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—DRD4—conduct disorder	0.00925	0.00925	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CGA—conduct disorder	0.00886	0.00886	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—DRD4—conduct disorder	0.00853	0.00853	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—DRD4—conduct disorder	0.0084	0.0084	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CGA—conduct disorder	0.00818	0.00818	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—HTR2A—conduct disorder	0.00776	0.00776	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—DRD4—conduct disorder	0.00775	0.00775	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—WASF1—conduct disorder	0.0071	0.0071	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—DRD4—conduct disorder	0.00672	0.00672	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—WASF1—conduct disorder	0.00655	0.00655	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CGA—conduct disorder	0.00644	0.00644	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—DRD4—conduct disorder	0.0061	0.0061	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—HTR2A—conduct disorder	0.00603	0.00603	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—HTR2A—conduct disorder	0.00557	0.00557	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—HTR2A—conduct disorder	0.00548	0.00548	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—WASF1—conduct disorder	0.00516	0.00516	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—HTR2A—conduct disorder	0.00506	0.00506	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—DRD4—conduct disorder	0.00496	0.00496	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—DRD4—conduct disorder	0.00458	0.00458	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—HTR2A—conduct disorder	0.00438	0.00438	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—HTR2A—conduct disorder	0.00398	0.00398	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—DRD4—conduct disorder	0.0036	0.0036	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—HTR2A—conduct disorder	0.00324	0.00324	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—HTR2A—conduct disorder	0.00299	0.00299	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—HTR2A—conduct disorder	0.00235	0.00235	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—EP300—conduct disorder	0.00171	0.00171	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—EP300—conduct disorder	0.00158	0.00158	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—EP300—conduct disorder	0.00125	0.00125	CbGpPWpGaD
